17th Oct 2013 17:35
Oxford Pharmascience Group plc ("Oxford Pharmascience" or "the Company")
Change of shareholder ownership and change of Director
Change of shareholder ownership and director's interest
ORA Capital Partners Limited ("ORA") has announced that the distribution to its shareholders of its 23.0% interest in the issued share capital of Oxford Pharmascience (as previously held through its wholly owned subsidiary ORA (Guernsey) Limited) completed today 17 October 2013. This comprises part of the distribution in specie by ORA of its entire quoted portfolio company equity holdings, following shareholder approval at the ORA General Meeting on 14 October 2013.
Consequent to the above distribution by ORA, Oxford Pharmasciencehas today also been notified of the following changes in interests in the issued share capital of the Company:
Shares received as part of distribution in specie by ORA | Resultant interest in shares of the Company | Resultant % of issued share capital of the Company | |
*Richard Griffiths
| 168,662,260 | 168,722,260 | 18.80% |
*Blake Holdings Limited
| 160,941,640 | 160,941,640 | 17.93% |
David Norwood (a Director of the Company) | 7,424,333 | 104,938,633 | 11.69% |
*Blake Holdings Limited is controlled by Richard Griffiths, hence the interest of Blake Holdings Limited is also included within that of Mr Griffiths.
Change of Director
Following the decision by ORA to distribute in specie its holding in the Company to ORA's shareholders, Mike Bretherton stepped down from the Oxford Pharmascience board yesterday 16 October 2013. Mike, who relocated to Guernsey earlier this year and is also a director of ORA, has been a valuable member of our team and we wish him well for the future.
Mike has been replaced as Finance Director by Chris Hill who has been our Company secretary for approximately three years and therefore knows us and our company well. Chris graduated in Economics and Public Policy in 2001 from Leeds Metropolitan University where he combined his studies with a professional rugby career. He then went on to gain his chartered accountancy qualification with Grant Thornton. Chris is also a director of Quoram Plc, an Investment Company listed on AIM.
The directors are pleased to welcome Chris to the board in what is an exciting time for Oxford Pharmascience as they continue to grow and evolve in to a drug re-development company.
The following information is disclosed in relation to Schedule Two paragraph (g) of the AIM Rules:
Mr Christopher James Hill (aged 33) has been a director of the following companies during the five years preceding the date of this announcement:
Current directorships | Previous directorships |
Quoram Plc | |
Antisoma Research Limited | |
Antisoma Ventures Limited (Dormant) | |
Antisoma Development Limited (Dormant) |
No further information is required to be disclosed pursuant to Schedule Two paragraph (g).
For further information:
Oxford Pharmascience Group Plc
Nigel Theobald, Chief Executive +44 1865 854874
N+1 Singer
Shaun Dobson/Jenny Wyllie +44 20 7496 3000
About Oxford Pharmascience Group Plc
Oxford Pharmascience Group Plc uses a range of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take. The Company does not manufacture or sell its own pharmaceutical products direct to consumers but instead seeks to license its technologies and dossiers to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios.
Oxford Pharmascience Group Plc focuses on existing medicines that are proven to be safe and effective but nevertheless still have associated issues and side effects often affecting compliance. By working with such medicines the Company is able to develop new innovative products for a fraction of the cost, in much quicker timescales and without the high risk of failure associated with developing new drugs.
Related Shares:
ABA.L